We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App





Test Kit to Measure TTV Titer and Assessing Results Using Algorithm Could Improve COVID-19 Diagnosis

By LabMedica International staff writers
Posted on 08 Nov 2021
Print article
Image: Test Kit to Measure TTV Titer and Assessing Results Using Algorithm Could Improve COVID-19 Diagnosis (Photo courtesy of IMT-USP)
Image: Test Kit to Measure TTV Titer and Assessing Results Using Algorithm Could Improve COVID-19 Diagnosis (Photo courtesy of IMT-USP)

A study has shown that levels of Torquetenovirus (TTV), an apparently inoffensive virus considered an indicator of immunodepression, tend to be higher in people infected by SARS-CoV-2.

The new study by researchers at the University of São Paulo (São Paulo, Brazil) suggests that TTV load in people infected by SARS-CoV-2 can be used as a marker of COVID-19 severity and recovery. TTV is one of the viruses most frequently found in the human organism. It is also common in monkeys and domestic animals. Its presence has not been associated with any known disease, but its excessive replication is a sign that something is wrong with the immune system. The correlation between high TTV load and immunosuppression has been used in medicine in certain contexts, such as monitoring transplant patients who take medication to prevent rejection of the transplanted organ.

In the study, the researchers analyzed samples from patients to investigate how the elimination of SARS-CoV-2 varies over time in different body fluids, such as blood, urine and saliva. All patients included in the study had mild or moderate COVID-19. TTV and SARS-CoV-2 viral loads were measured in saliva samples.

“We used analyzed samples from 91 patients diagnosed with SARS-CoV-2 by RT-PCR, and from 126 people with flu symptoms who tested negative. We found TTV titer to be higher in subjects infected by the novel coronavirus. The higher the titer, the longer they remained sick. Symptoms disappeared as viral load decreased. In uninfected subjects, TTV titer remained stable throughout the symptomatic period,” said Maria Cássia Mendes-Correa, a professor at the Medical School (FM-USP). “The results showed that TTV can indeed serve as a marker of the progression and outcome of this disease. The more symptomatic the patient, the higher the TTV load in the sample.”

Related Links:
University of São Paulo 

Gold Supplier
COVID-19 Real Time RT-PCR Kit
respiraScreen 1
New
Automatic Urine Sediment Analyzer
US-120
New
3-Part Diff Auto Hematology Analyzer
Cellagon 3
New
Automated Molecular Diagnostic Analyzer
AutoMolec 1600

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: The ultrarapid genome sequencing pipeline, indicating all processes from sample collection to a diagnosis. Vertically stacked processes are run in parallel (Photo courtesy of Stanford University)

Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting

A genetic diagnosis can guide clinical management and improve prognosis in critically ill patients, and much effort has gone into developing methods that result in rapid, reliable results.... Read more

Hematology

view channel
Image: My Qualiris QC (Photo courtesy of Stago)

Stago Launches New My Qualiris QC Website for Brand-New User Experience

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.... Read more

Industry

view channel
Illustration

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.